Get the Stockscreener App
2.05
5.09%
-0.11
After Hours:
2.04
-0.010
-0.49%
Innate Pharma Adr stock is traded at $2.05, with a volume of 48,364.
It is down -5.09% in the last 24 hours and up +21.63% over the past month.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
See More
Previous Close:
$2.16
Open:
$2.08
24h Volume:
48,364
Relative Volume:
0.11
Market Cap:
$169.71M
Revenue:
$47.04M
Net Income/Loss:
$-63.98M
P/E Ratio:
-2.5422
EPS:
-0.8064
Net Cash Flow:
$-34.39M
1W Performance:
-32.12%
1M Performance:
+21.63%
6M Performance:
-4.21%
1Y Performance:
-23.65%
1-Day Range:
$2.025
$2.10
1-Week Range:
$2.025
$2.67
52-Week Range:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
2.05 | 169.71M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-15-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-24-20 | Initiated | Goldman | Neutral |
Innate Pharma Adr Stock (IPHA) Latest News
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Innate Pharma S.A. ADR (IPHA-Q) QuotePress Release - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update - The Globe and Mail
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update - The Globe and Mail
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag - Yahoo Movies UK
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting - Investing.com India
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Innate Pharma Adr Stock (IPHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):